Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Capsicum→

Capsicum Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
8023-77-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Capsicum fruit extractcapsaicinoid-containing topical counterirritant
Mechanism of action
Capsaicinoids activate TRPV1 receptors on peripheral sensory neurons, initially producing warmth or burning followed by functional desensitisation and reduced nociceptive signalling with repeated exposure.
Indications / reported uses
  • Topical symptomatic relief of minor muscle and joint pain in authorised external analgesic products; exact capsaicinoid concentration and formulation determine use

Sources: US eCFR — External analgesic drug products, 21 CFR Part 348 · NCCIH — Capsaicin and topical pain relief · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Capsicum Environmental Risk Assessment (ERA) (the Capsicum ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.